

## ***Supportive material***

---

### Publications in scientific journals

- **D. Manou**, P. Bouris, D. Kletsas, M. Götte, B. Greve, A. Moustakas, N.K. Karamanos, A.D. Theocharis, Serglycin activates pro-tumorigenic signaling and controls glioblastoma cell stemness, differentiation and invasive potential, *Matrix Biology Plus* 6-7 (2020) 100033.
- **D. Manou**, N.K. Karamanos, A.D. Theocharis, Tumorigenic functions of serglycin: Regulatory roles in epithelial to mesenchymal transition and oncogenic signaling, *Seminars in cancer biology* (2019)
- D. Theocharis, **D. Manou**, N.K. Karamanos. Multitasking roles for extracellular matrix in disease. *The FEBS Journal*. doi: 10.1111/febs.14818 (2019)
- **Manou D.**, Caon, I., Bouris, P., Triantaphyllidou, I-E., Giaroni, C., Passi, A., Karamanos N.K., Vigetti, D., Theocharis A.D. The complex interplay between extracellular matrix and cells in tissues. *Methods in molecular biology* 1925, doi: 10.1007/978-1-4939-9133-4\_1 (2019)
- P. Bouris, **D. Manou**, A. Sopaki-Valalaki, A. Kolokotroni, A. Moustakas, A. Kapoor, R.V. Iozzo, N.K. Karamanos, A.D. Theocharis, Serglycin promotes breast cancer cell aggressiveness: Induction of epithelial to mesenchymal transition, proteolytic activity and IL-8 signaling, *Matrix Biology* (2018)
- Piperigkou, Z., **Manou, D.**, Karamanou, K. & Theocharis, A. D. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer. *Methods in molecular biology* 1731, 325-348, doi:10.1007/978-1-4939-7595-2\_27 (2018)

### Chapters in International Books

- **Manou, D.**, Caon, I., Bouris, P., Triantaphyllidou, I-E., Giaroni, C., Passi, A., Karamanos N.K., Vigetti, D., Theocharis A.D. The complex interplay between extracellular matrix and cells in tissues. In: Vigetti D., Theocharis A. (eds) *The extracellular matrix: Methods and Protocols*. Springer Science+ Business media, LLC, part of Springer Nature (2019)
- Piperigkou, Z., **Manou, D.**, Karamanou, K. & Theocharis, A. D. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer. In: Cal S., Obaya A. (eds) *Proteases and Cancer*. Humana Press, New York, NY (2018)

### Oral Presentations

#### In International Conferences

- *Serglycin drives the malignant phenotype affecting cell properties, inflammation and signalling.* **D. Manou**, P. Bouris, M. Golfinopoulou, A. D. Theocharis. *FEBS Advanced Lecture Course*. "Matrix Pathobiology, Signaling and Molecular Targets" (7<sup>th</sup> FEBS-MPST 2019), 02-07 May 2019, Porto Heli, Greece.
- *Serglycin is an accomplice of the aggressiveness of glioblastoma cells.* **D. Manou**, P. Bouris, D. Kletsas, N.K. Karamanos, A.D. Theocharis. *FEBS Advanced Lecture Course*. "Extracellular Matrix: Cell regulation, Epigenetics and Modeling" (FEBS-ECM 2018), 27 Sep-02 Oct 2018, Patras, Greece.
- *Suppression of serglycin decreases glioblastoma cell aggressiveness.* **D. Manou**, P. Bouris, D. Kletsas, T.M. Reine, S.O. Kolset, A.D. Theocharis. *FEBS Advanced Lecture Course*. "Matrix Pathobiology, Signaling and Molecular Targets" (6<sup>th</sup> FEBS-MPST 2017), 25-30 May 2017,

Spetses, Greece.

- *Serglycin as a key proteoglycan in cellular effectors, signaling and functional properties of ERalpha silenced breast cancer cells.* Achilleas D.Theocharis, Panagiotis Bouris, Anastasia Sopaki-Valalaki, **Dimitra Manou**, Anthi Kolokotroni, Aris Moustakas, Nikos K.Karamanos. 2<sup>nd</sup> MBE (Matrix Biology Europe) Conference, 11-14 June 2016, Athens, Greece.
- *Tumorigenic role of serglycin in breast cancer cells.* P.Bouris, A.Kolokotroni, A.Sopaki-Valalaki, **D.Manou**, N.K. Karamanos, A.D. Theocharis. FEBS Advanced Lecture Course. "Matrix Pathobiology, Signaling and Molecular Targets" (5<sup>th</sup> FEBS-MPST), 24-29 September, Rhodes, Greece.

#### In Panhellenic Conferences

- *Serglycin instigates the aggressive phenotype of glioblastoma cells.* **Dimitra Manou**, Panagiotis Bouris, Dimitris Kletsas, Nikos K.Karamanos, Achilleas Theocharis. 69<sup>th</sup> Congress of the Hellenic Society of Biochemistry and Molecular Biology, 23-25 November 2018, Larissa, Greece.
- *The emerging role of serglycin as a regulator of glioblastoma cell aggressiveness.* **Dimitra Manou**, Panagiotis Bouris, Dimitris Kletsas, Trine M. Reine, Svein O. Kolset, Nikos K. Karamanos, Achilleas D. Theocharis. 5<sup>th</sup> Annual New Scientists' Forum of Hellenic Society of Biochemistry and Molecular Biology, 9 November 2017, Athens, Greece.
- *Serglycin acts as a tumorigenic factor in several cellular aspects of breast cancer cells.* Panagiotis Bouris, Anthi Kolokotroni, Anastasia Sopaki-Valalaki, **Dimitra Manou**, Nikos K.Karamanos, Achilleas D. Theocharis. 66<sup>th</sup> Congress of the Hellenic Society of Biochemistry and Molecular Biology, 11-13 December 2015, Athens, Greece.
- *ER $\alpha$  mediates epithelial to mesenchymal transition and expression of specific matrix effectors in breast cancer cells.* Panagiotis Bouris, Spyros S. Skandalis, Zoi Piperigkou, **Dimitra Manou**, Aristidis Moustakas, Achilleas D. Theocharis, Nikos K. Karamanos. 65<sup>th</sup> Congress of the Hellenic Society of Biochemistry and Molecular Biology, 28-30 November 2014, Thessaloniki, Greece.

#### Posters

#### In International Conferences

- The 44<sup>th</sup> FEBS Congress, 6-11 July 2019, Krakow, Poland
  - Loss of proteoglycan serglycin represses aggressive characteristics of glioblastoma cells. **D. Manou**, P. Bouris, D. Kletsas, M. Götte, B. Greve, N. K. Karamanos, A. D. Theocharis
- FEBS Advanced Lecture Course. "Extracellular Matrix: Cell regulation, Epigenetics and Modeling" (FEBS-ECM 2018), 27 Sep-02 Oct 2018, Patras, Greece.
  - *Serglycin is an accomplice of the aggressiveness of glioblastoma cells.* **D.Manou**, P.Bouris, D.Kletsas, N.K. Karamanos, A.D.Theocharis.
- FEBS Advanced Lecture Course. "Matrix Pathobiology, Signaling and Molecular Targets". (6<sup>th</sup>FEBS-MPST 2017), 25-30 May 2017, Spetses, Greece.
  - *Suppression of serglycin decreases glioblastoma cell aggressiveness.* **D. Manou**, P.Bouris, D. Kletsas, T.M. Reine, S.O. Kolset, A.D. Theocharis.
  - *Src kinases affect aggressiveness and the expression of proteolytic network molecules in ER $\alpha$  suppressed breast cancer cells.* A. Papargyriou, Z. Piperigkou, P. Bouris, **D. Manou**, N.K. Karamanos, A.D. Theocharis.
- 2<sup>nd</sup>MBE (Matrix Biology Europe) Conference, 11-14 June 2016, Athens, Greece.
  - *The effect of serglycin's suppression on various cellular aspects of glioblastoma cell line LN-18.* **Dimitra Manou**, Panagiotis Bouris, Anastasia Sopaki-Valalaki, Anthi Kolokotroni, Achilleas D. Theocharis.
  - *Inhibition of intracellular kinases affects cell aggressiveness and expression of proteolytic*

*network molecules in ER $\alpha$  suppressed breast cancer cells.* A. Papargyriou, A. Sopaki-Valalaki, P. Bouris, **D. Manou**, A. Moustakas, N.K. Karamanos, A.D. Theocharis.

- *Suppression of ER $\alpha$  induces the activation of TGF- $\beta$  and IL-8 pathways in breast cancer cells.* A. Sopaki-Valalaki, A. Moustakas, P. Bouris, **D. Manou**, A. Kolokotroni, N.K. Karamanos, A.D. Theocharis.
- FEBS Advanced Lecture Course. 'Matrix Pathobiology, Signaling and Molecular Targets' (5<sup>th</sup> FEBS-MPST 2015), September 24-29 2015, Rhodes, Greece
  - *Suppression of serglycin affects cell behaviour and gene expression of glioblastoma cell lines.* **D. Manou**, P. Bouris, A. Sopaki-Valalaki, A. Kolokotroni, A.D. Theocharis.
  - *The inhibition of IL-8 pathway reduces the aggressiveness of ER $\alpha$  suppressed MCF-7 breast cancer cells.* A. Sopaki-Valalaki, P. Bouris, **D. Manou**, A. Kolokotroni, N.K. Karamanos, A.D. Theocharis.
  - *Tumorigenic role of serglycin in breast cancer cells.* P.Bouris, A. Kolokotroni, A. Sopaki-Valalaki, **D. Manou**, N.K Karamanos, A.D.Theocharis.

#### In Panhellenic Conferences

- 7<sup>th</sup> Annual New Scientists' Forum of Hellenic Society of Biochemistry and Molecular Biology, 28 November 2019 & 70<sup>th</sup> Congress of the Hellenic Society of Biochemistry and Molecular Biology (HSBMB), 29 November -01 December 2019, Athens, Greece
  - *Serglycin modulates the aggressive behaviour and differentiation of glioblastoma cells.* **Dimitra Manou**, Maria Aggeliki Golfinopoulou, Panagiotis Bouris, Dimitris Kletsas, Martin Goette, Burkhard Greve, Nikos N. Karamanos, Achilleas D. Theocharis
  - *Serglycin and HER-2 regulate the migratory and proteolytic properties of glioblastoma cells LN-18.* Maria Aggeliki Golfinopoulou, **Dimitra Manou**, Nikos K. Karamanos, Achilleas D. Theocharis.
- 6<sup>th</sup> Annual New Scientists' Forum of Hellenic Society of Biochemistry and Molecular Biology, 22 November 2018, Larissa, Greece.
  - *Serglycin instigates the aggressive phenotype of glioblastoma cells.* **Dimitra Manou**, Panagiotis Bouris, Dimitris Kletsas, Nikos K.Karamanos, Achilleas Theocharis.
- 68<sup>th</sup> Congress of the Hellenic Society of Biochemistry and Molecular Biology, 9 November 2017, Athens.
  - *The emerging role of serglycin as a regulator of glioblastoma cell aggressiveness.* **Dimitra Manou**, Panagiotis Bouris, Dimitris Kletsas, Trine M. Reine, Svein O. Kolset, Nikos K. Karamanos, Achilleas D. Theocharis.
- 67<sup>th</sup> Congress of the Hellenic Society of Biochemistry and Molecular Biology (HSBMB), 25-27 November 2016, Ioannina. &
- 4<sup>th</sup> Annual New Scientists' Forum of HSBMB, 24 November 2016, Ioannina.
  - *Serglycin acts as a promoter of aggressiveness in breast cancer cells.* Anti Kolokotroni, Panagiotis Bouris, Anastasia Sopaki-Valalaki, **Dimitra Manou**, Xenia Didimoti, Angeliki Meintani, Nikos K. Karamanos, Achilleas D. Theocharis.
  - *Suppression of ER $\alpha$  induces the activation of TGF- $\beta$  and IL-8 pathways in breast cancer cells.* Anastasia Sopaki-Valalaki, Aristidis Moustakas, Panagiotis Bouris, **Dimitra Manou**, Anthi Kolokotroni, Nikos K. Karamanos, Achilleas D. Theocharis.
- 66<sup>th</sup> Congress of the Hellenic Society of Biochemistry and Molecular Biology (HSBMB), 11-13 December 2015, Athens.
  - *The impact of serglycin's suppression on the behavior and the gene expression of GBM cell lines.* **Dimitra Manou**, Panagiotis Bouris, Anastasia Sopaki-Valalaki, Anthi Kolokotroni, Achilleas D.Theocharis.
  - *Effect of IL-8 signaling pathway in functional properties of ER $\alpha$  suppressed MCF-7 cells.* Anastasia Sopaki-Valalaki, Panagiotis Bouris, **Dimitra Manou**, Anthi Kolokotroni, Nikos K.

Karamanos, Achilleas D. Theocharis

- *Serglycin acts as a tumorigenic factor in several cellular aspects of breast cancer cells.*  
Panagiotis Bouris, Anthi Kolokotroni, Anastasia Sopaki-Valalaki, **Dimitra Manou**, Nikos K. Karamanos, Achilleas D. Theocharis
- 3<sup>th</sup> Annual New Scientists' Forum of HSBMB, 10 December 2015, Athens.
  - *The impact of serglycin's suppression on the behavior and the gene expression of GBM cell lines.* **Dimitra Manou**, Panagiotis Bouris, Anastasia Sopaki-Valalaki, Anthi Kolokotroni, Achilleas D.Theocharis
  - *Effect of IL-8 signaling pathway in functional properties of ERα suppressed MCF-7 cells.*  
Anastasia Sopaki-Valalaki, Panagiotis Bouris, **Dimitra Manou**, Anthi Kolokotroni, Nikos K. Karamanos, Achilleas D. Theocharis